Abstract
The tripeptide glycine-proline-glutamate (GPE) is the naturally cleaved N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) in brain tissues by an acid protease. Although GPE does not bind to IGF-1 receptors and its mode of action is not clear, in vitro studies have demonstrated its ability to stimulate acetylcholine and dopamine release, as well as to protect neurones from diverse induced brain injures. More importantly, GPE has been shown to have potent neuroprotective effects in numerous animal models of hypoxic-ischemic brain injury and neurodegenerative diseases such as Parkinsons, Alzheimers and Huntingtons diseases. As a consequence, GPE was suggested to be a potential target for the rational design of neuroprotective agents. Unfortunately, the use of GPE as a therapeutic agent is limited because of its unfavorable biochemical and pharmacokinetic properties. This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system (CNS) injures and neurodegenerative disorders.
Keywords: Glycine-proline-glutamate, GPE analogues, macrocyclic GPE analogues, structure-activity relationships, neuroprotective agents, neurodegenerative disease, hypoxic-ischemic brain injury, Huntington's diseases, neurodegenerative diseases, Ligand-receptor interactions, amino-terminal glycine, carboxy-teminal glutamate, postoperative period, proline-analogues
Mini-Reviews in Medicinal Chemistry
Title: GPE and GPE Analogues as Promising Neuroprotective Agents
Volume: 12 Issue: 1
Author(s): I. Cacciatore, C. Cornacchia, L. Baldassarre, E. Fornasari, A. Mollica, A. Stefanucci and F. Pinnen
Affiliation:
Keywords: Glycine-proline-glutamate, GPE analogues, macrocyclic GPE analogues, structure-activity relationships, neuroprotective agents, neurodegenerative disease, hypoxic-ischemic brain injury, Huntington's diseases, neurodegenerative diseases, Ligand-receptor interactions, amino-terminal glycine, carboxy-teminal glutamate, postoperative period, proline-analogues
Abstract: The tripeptide glycine-proline-glutamate (GPE) is the naturally cleaved N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) in brain tissues by an acid protease. Although GPE does not bind to IGF-1 receptors and its mode of action is not clear, in vitro studies have demonstrated its ability to stimulate acetylcholine and dopamine release, as well as to protect neurones from diverse induced brain injures. More importantly, GPE has been shown to have potent neuroprotective effects in numerous animal models of hypoxic-ischemic brain injury and neurodegenerative diseases such as Parkinsons, Alzheimers and Huntingtons diseases. As a consequence, GPE was suggested to be a potential target for the rational design of neuroprotective agents. Unfortunately, the use of GPE as a therapeutic agent is limited because of its unfavorable biochemical and pharmacokinetic properties. This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system (CNS) injures and neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Cacciatore I., Cornacchia C., Baldassarre L., Fornasari E., Mollica A., Stefanucci A. and Pinnen F., GPE and GPE Analogues as Promising Neuroprotective Agents, Mini-Reviews in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/138955712798868995
DOI https://dx.doi.org/10.2174/138955712798868995 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism Nitric Oxide Production during Cerebral Ischemia and Reperfusion in eNOS- and nNOS-Knockout Mice
Current Neurovascular Research Genetic Markers in Biological Fluids for Aging-Related Major Neurocognitive Disorder
Current Alzheimer Research Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Aminoacid Support in the Prevention of Diabetes and Diabetic Complications
Current Protein & Peptide Science Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design Psychosocial Factors and Central Sensitivity Syndromes
Current Rheumatology Reviews Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design Thermotropic and Spectroscopic Behavior of Skin: Relationship with Percutaneous Permeation Enhancement
Current Drug Delivery Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Treating Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases
Current Medicinal Chemistry Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines
Current Stem Cell Research & Therapy